Editas Medicine to Participate in Upcoming Investor Conferences

CAMBRIDGE, Mass., Oct. 01, 2019 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that management will participate in the following upcoming investor conferences: 

Cell & Gene Meeting on the MesaPanel: What does the future hold for gene editing?Date: Friday, October 4, 2019Time: 9:45 a.m. PT

Chardan 3rd Annual Genetic Medicines ConferenceDate: Monday, October 7, 2019

Fireside ChatTime: 10:30 a.m. ET

Panel: What’s next in gene editing technologies?Time: 12:45 p.m. ETLocation: New York, NY

The events will be webcast live and may be accessed on the Editas Medicine website in the Investors and Media section. Archived recordings will be available for approximately 30 days following the events.

About Editas Medicine As a leading genome editing company, Editas Medicine is focused on translating the power and potential of the CRISPR/Cas9 and CRISPR/Cpf1 (also known as Cas12a) genome editing systems into a robust pipeline of treatments for people living with serious diseases around the world. Editas Medicine aims to discover, develop, manufacture, and commercialize transformative, durable, precision genomic medicines for a broad class of diseases. For the latest information and scientific presentations, please visit www.editasmedicine.com.    

Contacts:InvestorsMark Mullikin(617) 401-9083[email protected]

MediaCristi Barnett(617) 401-0113 [email protected]

Source: Editas Medicine, Inc.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Northeast Ohio Medical University (NEOMED) Mobilizes Global Health Resources for Nepal Disaster Response and Recovery
• Silver Hammer and Stroud Resources Announce Updated Mineral Resource Estimate for the Santo Domingo Silver-Gold Project, Mexico
• Takeda Receives U.S. FDA Approval of MIMRYLO™ (rusfertide), Marking a Potential Shift in the Treatment Paradigm for Polycythemia Vera